Patents by Inventor Yeng-Jeng Shaw

Yeng-Jeng Shaw has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SMALL MOLECULE INHIBITORS OF THE ANDROGEN RECEPTOR ACTIVITY AND/OR EXPRESSION AND USES THEREOF
    Publication number: 20220062278
    Abstract: This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a piperazine (or similar) structure which function as antagonists of androgen receptor activity, and their use as therapeutics for the treatment of cancer (e.g., castration-resistant prostate cancer) and other conditions characterized with androgen receptor activity and/or androgen receptor expression.
    Type: Application
    Filed: December 11, 2019
    Publication date: March 3, 2022
    Inventors: Christopher Hulme, Yeng-Jeng Shaw, Vijay Gokhale
  • Small molecule inhibitors of DYRK1A and uses thereof
    Patent number: 10730842
    Abstract: This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a benzimidazole or imidazopyridine structure which function as inhibitors of DYRK1A protein, and their use as therapeutics for the treatment of Alzheimer's disease, Down syndrome, glioblastoma, autoimmune diseases, inflammatory disorders (e.g., airway inflammation), and other diseases.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: August 4, 2020
    Assignees: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA, THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE
    Inventors: Christopher Hulme, Travis Dunckley, Yeng-Jeng Shaw
  • SMALL MOLECULE INHIBITORS OF DYRK1A AND USES THEREOF
    Publication number: 20190062284
    Abstract: This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a benzimidazole or imidazopyridine structure which function as inhibitors of DYRK1A protein, and their use as therapeutics for the treatment of Alzheimer's disease, Down syndrome, glioblastoma, autoimmune diseases, inflammatory disorders (e.g., airway inflammation), and other diseases.
    Type: Application
    Filed: September 2, 2016
    Publication date: February 28, 2019
    Applicants: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA, THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE
    Inventors: Christopher HULME, Travis DUNCKLEY, Yeng-Jeng SHAW
  • Antitumor agents and methods of their use
    Patent number: 8377948
    Abstract: Antitumor compounds based on the ?1-adrenoceptor antagonist, doxazosin, as well as compositions and methods of use. The disclosed compounds induce apoptosis in cancer cells.
    Type: Grant
    Filed: June 17, 2005
    Date of Patent: February 19, 2013
    Assignee: The Ohio State University Research Foundation
    Inventors: Ching-Shih Chen, Yeng-Jeng Shaw, Jason B. Garrison, Natasha Kyprianou
  • NOVEL ANTITUMOR AGENTS AND METHODS OF THEIR USE
    Publication number: 20090048265
    Abstract: Antitumor compounds based on the ?1-adrenoceptor antagonist, doxazosin, as well as compositions and methods of use. The disclosed compounds induce apoptosis in cancer cells.
    Type: Application
    Filed: June 17, 2005
    Publication date: February 19, 2009
    Applicant: THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION
    Inventors: Ching-Shih Chen, Yeng-Jeng Shaw